scholarly journals P0749THE ASSOCIATION OF VISCERAL ADIPOSITY INDEX WITH PROGRESSION OF CHRONIC KIDNEY DISEASE

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Zelal Adibelli ◽  
Soycan Mizrak ◽  
Cevdet Duran
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Visceral Adiposity ◽  
University Hospital ◽  
Visceral Adiposity Index ◽  
Metabolic Function ◽  
Adiposity Index ◽  
Important Health ◽  
The Mean ◽  
Egfr Decline

Abstract Background and Aims Obesity is becoming an important health problem as its prevalence is increasing. Obesity is also a factor that causes an increase in chronic kidney disease (CKD) cases by facilitating the development of diabetes and hypertension, which leads to CKD, and by a direct effect on the kidney and endocrine mechanism. Obesity is generally defined by body mass index (BMI), which is not a good indicator for visceral adipose tissue (VAT), as visceral fat has been shown to be more metabolically active. A new method called the visceral adiposity index (VAI) has been developed, which is considered to be an indicator for the metabolic function of VAT. Previous studies have confirmed the association between the VAI and CKD prevalence. In this study, we attempted to investigate the association between estimated glomerular filtration rate (eGFR) decline and visceral adiposity. Method Data were collected from 129 patients aged 18-80 years with stage 2-5 CKD and not on dialysis; these patients were followed up in the Nephrology Department of Usak University Hospital between December 2017 and November 2018. Results Of 129 patients with stage 2-5 CKD enrolled in this study, 64 (40.6%) were females and 66 (59.4%) were males. The mean age was 66.8 (35-80 years). The mean VAI values of patients were 2.86±1.63, and the mean eGFR decline was -12.8±19.0 ml/min/1.73m2. No correlation was observed between the VAI values and decline in eGFR in 1 year. Patients with DM had statistically significant higher eGFR decline (p=0.04) and higher VAI values (p=0.03). Conclusion The VAI, which is used to assess the metabolic function of VAT, was not associated with the eGFR decline in 1 year for patients with stage 2-5 CKD.

scholarly journals The Visceral Adiposity Index Is a Predictor of Incident Chronic Kidney Disease: A Population-Based Longitudinal Study

2020 ◽  
Vol 45 (3) ◽  
pp. 407-418 ◽  
Author(s):  
Ryo Bamba ◽  
Takuro Okamura ◽  
Yoshitaka Hashimoto ◽  
Masahide Hamaguchi ◽  
Akihiro Obora ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Visceral Adiposity ◽  
Visceral Adiposity Index ◽  
Historical Cohort ◽  
Men And Women ◽  
Adiposity Index ◽  
Incident Chronic Kidney Disease ◽  
The Impact

Background and Aims: Visceral adiposity index (VAI), calculated with body mass index, high density lipoprotein-cholesterol, triglycerides and waist circumference, has been proposed as a marker of visceral fat accumulation and dysfunction in adipose tissue. Methods: The impact of VAI on incident chronic kidney disease (CKD) in a historical cohort study of 15,159 (8,260 men and 6,899 women) participants was investigated. CKD was defined when estimated glomerular filtration rate was <60 mL/min/1.73 m2 or proteinuria (positive: ≥1+). We divided the participants into 2 groups according to sex and into quartiles according to VAI (Q1–4). We performed Cox proportional hazard models, adjusting for age, smoking status, exercise, alcohol consumption, systolic blood pressure, hemoglobin A1c, uric acid, and creatinine. Results: During the median 3.3-year follow-up for men and 3.2-year follow-up for women, 1,078 participants (629 men and 449 women) developed CKD. The 4,000 days cumulative incidence rate of CKD for men and women were 3.7 and 3.9% in Q1, 5.2 and 5.9% in Q2, 6.5 and 7.0% in Q3, and 8.4 and 9.3% in Q4 respectively. Compared to Q1, the hazard ratios of incident CKD in Q2, Q3 and Q4 for men and women were 1.23 (95% CI 0.91–1.66, p = 0.184) and 1.30 (0.87–1.96, p = 0.203), 1.42 (1.06–1.90, p = 0.018) and 1.38 (0.94–2.05, p = 0.105), and 1.51 (1.12–2.02, p = 0.006) and 1.65 (1.12–2.46, p = 0.013) respectively. Additionally, the area under the curve of VAI for incidence of CKD was superior to that of VAI in men (0.595 vs. 0.552, p < 0.001) and equal to in women (0.597 vs. 0.591, p = 0.708). Conclusions: The VAI can be a predictor of incident CKD.

scholarly journals A study of visceral adiposity index as a diagnostic index in gestational diabetes mellitus in a tertiary care centre

2017 ◽  
Vol 6 (4) ◽  
pp. 1561
Author(s):  
Padmalatha Dakshnamurthy ◽  
Shaanthy Gunasingh Thangiah Kasirajan ◽  
Indhumathi Nachiyar ◽  
Mangala Geetha ◽  
Kannan Rajendran
Keyword(s):  
Pregnant Women ◽  
Tertiary Care ◽  
Visceral Adiposity ◽  
P Value ◽  
Visceral Adiposity Index ◽  
Care Centre ◽  
Tertiary Care Centre ◽  
Adiposity Index ◽  
The Mean ◽  
Diagnostic Index

Background: Gestational Diabetes Mellitus is an emerging problem which affects pregnant women all over the world particularly in India. Early detection reduces adverse maternal and foetal outcome. Elevated central adiposity is a modifiable risk factor for abnormal glucose homeostasis in pregnancy and GDM. The Visceral Adiposity Index (VAI) is a gender-specific index of fat distribution and assessment.Methods: It is a hospital based, case control study among the subjects who attended a tertiary care centre. cases were 30 pregnant women newly diagnosed with GDM in their 2nd trimester, and Controls were 30 apparently healthy pregnant women in their 2nd trimester without risk factors for GDM such as obesity and family history for diabetes. Visceral Adiposity Index (VAI) was calculated using the formula (Waist circumference (WC)/ {36.58 +(1.89xBMI)}) x(TGL/0.81) x (1.52/HDL) where WC is expressed in cm, BMI in Kg/m2, TG in mmol/L, HDL in mmol/L.Results: The mean age of patients with GDM was higher when compared to controls (28.17 ± 3.34vs 24.40±3.07) and this difference was statistically significant (p value < 0.0001). The average weights were significantly different. The mean Body Mass Index (BMI) and waist circumference (WC) was 23.59 ± 4.19 and 88.46 ± 7.10 respectively among controls and 29.85 ±4.52 and 102.12 ± 6.96 respectively among GDM patients and these differences were highly significant (p value<0.0001). The lipid profile of these patients showed a significantly higher value of Triglycerides among patients.Conclusions: This study correlates GDM with Visceral adiposity index and found that the index to be elevated in the GDM group. The increased VAI in GDM patients shows their elevated adipose tissue distribution.  VAI is less invasive and cost effective, can be used as a diagnostic index in GDM.

Maximum Glomerular Filtration Decline Rate is Associated with Mortality and Poor Renal Outcome in Chronic Kidney Disease Patients

2019 ◽  
Vol 48 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Hung-Chih Chen ◽  
Hsuan-Jen Lin ◽  
Chiu-Ching Huang ◽  
Chiz-Tzung Chang ◽  
Che-Yi Chou
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Primary Outcome ◽  
Renin Angiotensin System ◽  
University Hospital ◽  
Renal Outcome ◽  
Increased Risk ◽  
Decline Rate ◽  
Gfr Decline ◽  
Egfr Decline

Background: Glomerular filtrate rate (GFR) decline is associated with increased risk of dialysis in patients with chronic kidney disease (CKD). It is unclear whether the maximum, the minimum, or the average of GFR decline rate is associated with the risk of mortality and the initiation of renal replacement therapy (RRT). We investigated prognostic role of the maximum, the minimum, and the average of GFR decline rate in patients with CKD not yet on dialysis. Methods: Patients, enrolled in the CKD program of China Medical University Hospital between July 2004 and Aug 2013, with CKD stages 3–5 (estimated GFR [eGFR] < 60 mL/min/1.73 m2) not yet on dialysis were analyzed. Primary outcome was a composite of mortality and RRT. The association between 3 readings of GFR decline rate and primary outcome was analyzed using Cox proportional hazard regression. Results: We analyzed 815 patients aged 75 (interquartile range [IQR] 65–82) years with a median follow-up of 5.2 years (IQR 3.9–6.9). The maximum of eGFR decline rate was associated with the primary outcome (hazard ratio 2.19, 95% CI 1.16–4.12, p = 0.015), independent of age, gender, diabetes, cerebrovascular accident, smoking, baseline eGFR, serum albumin, calcium, urine protein/creatinine ratio, usage of renin-angiotensin system blockade. The minimum and the average of eGFR decline rate were not associated with the primary outcome. Conclusions: The maximum of GFR decline rate was associated with mortality and poor renal outcome in CKD patients, independent of other contributive confounders.

Correlation of Serum Sclerostin Levels with Carotid Intima Media Thickness in Chronic Kidney Disease Hemodialysis

2020 ◽  
Vol 6 (1) ◽  
pp. 18-26
Author(s):  
Adhi Permana ◽  
Ian Effendi ◽  
Taufik Indrajaya
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vascular Calcification ◽  
Ultrasound Examination ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Media Thickness ◽  
The Mean ◽  
Sclerostin Level ◽  
Hemodialysis Duration

Chronic kidney disease is associated with a high mortality rate, especially cardiovascular disease associated with mineral and bone disorders. Sclerostin is an inhibitor of Wnt signaling which has the effect of increasing the occurrence of vascular calcification in patients with chronic kidney disease. There are several studies that show different results. Carotid intima media thickness ultrasound examination is a tool to identify atherosclerosis which is part of vascular calcification. The aim of this study is to look at the correlation of sclerostin with carotid intima media thickness (CIMT) in patients with chronic kidney disease undergoing hemodialysis. In this cross section, the concentration of sclerostin was measured by examination of enzymed linked immunosorbent assay. CIMT measurement by ultrasound mode B examination. There were 40 patients in this study. The mean sclerostin level was 256.68 ± 127.76 pg / ml. Sclerostin levels are declared high if above 162 pg / ml there are 30 people. CIMT thickening was present in 11 patients. There was no significant correlation of serum sclerostin with CIMT in patients with chronic kidney disease undergoing hemodialysis (r-0.32 p0,847). In multivariate linear regression, hemodialysis duration is an independent factor that is significantly significant with CIMT. There was no significant correlation of serum sclerostin with CIMT in patients with chronic kidney disease undergoing hemodialysis.

Lesser eGFR Decline with Dulaglutide Regardless of Weight Changes in People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease (AWARD-7)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1066-P ◽  
Author(s):  
KATHERINE R. TUTTLE ◽  
MARK LAKSHMANAN ◽  
BRIAN L. RAYNER ◽  
ROBERT S. BUSCH ◽  
ALAN G. ZIMMERMANN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Weight Changes ◽  
Severe Chronic Kidney Disease ◽  
Egfr Decline
Sign in / Sign up

Export Citation Format

Share Document